Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

• Status: Terminated
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objectives:

1. Assess whether combined treatment with Levothyroxine and Liothyronine improves learning and memory.

2. Explore the relationship between T3 treatment and other domains of cognitive function, quality of life, and mood.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center

Criteria

Inclusion Criteria:

• All patients must have the diagnosis of hypothyroidism.

• Patients must be already on thyroid hormone replacement.

• Patients must be greater than or equal to 18 years old.

• Patients must have a diagnosis of a primary or secondary brain tumor and must have received prior radiation.

• Patients must have a life expectancy of at least 6 months.

Exclusion Criteria:

• Previously established dementing illness.

• Other medical conditions known to cause dementia.

• Significant psychiatric illness.

• Uncontrolled seizures.

• Acute or chronic pulmonary disease.

• Active severe infections.

• Signs or symptoms of coronary artery disease.

• History of congenital hypothyroidism, hyperthyroidism, thyroidectomy, 131I-therapy, or thyroid cancer.

• Paroxysmal supraventricular tachycardia, or any serious unstable medical condition.

• Inability to read and write in English.

• Patients must not be taking any medications that interfere with thyroid hormone metabolism (Beta-Adrenergic Blocking Agents, Antiarrhythmic drugs, Antipsychotic Agents, Tricyclic Antidepressants, Amiodarone, Iodine, Lithium, and Alpha-Interferon).